A systems approach to hemostasis and thrombosis
止血和血栓形成的系统方法
基本信息
- 批准号:10434811
- 负责人:
- 金额:$ 55.14万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-05-10 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:3-DimensionalAgonistAlpha GranuleAntibodiesAntiplatelet DrugsArchitectureArkansasArteriesBlood PlateletsBlood VesselsBlood flowBrainCarotid ArteriesClot retractionCoagulation ProcessCollaborationsComplexComputer ModelsConvectionCoronary arteryDefectDevicesDiffusionEngineeringEnvironmentEventFaceFibrinGoalsHeartHemorrhageHemostatic AgentsHemostatic functionHumanHybridsImageIndividualInjuryMeasuresMethodsMicrofluidic MicrochipsMicroscopyMolecularMusMyocardial InfarctionNatural ImmunityPathologicPhospholipidsPhysiologicalPlatelet ActivationPlatelet Count measurementProcessRegulationResearch PersonnelResolutionRoleScanning Electron MicroscopySchoolsSepsisShapesStrokeStructureStructure of jugular veinSurfaceSurgeonSyndromeSystemTestingThrombinThrombosisThrombusTissuesTranslatingTraumaUniversitiesVariantVeinsVenous ThrombosisWorkblood damagecerebrovascularcomputer studiesdensityimprovedin vivoinhibitorm-calpainmu-calpainnovelphysical propertyplatelet functionpreventreconstructionregional differenceresponsescale upsubmicronsystemic inflammatory responsethrombotictumor growthvascular injury
项目摘要
Project 3 Abstract
Platelet activation is critical for hemostasis and a contributing factor in thrombosis. Although recent studies have
highlighted roles for platelets in diverse processes, the rapid accumulation of large numbers of platelets remains
the hallmark of hemostasis and arterial thrombosis, and is the major focus of this project. Our recent studies in
the mouse microvasculature show that the hemostatic response to small injuries produces a relatively simple
structure in which a core of fully-activated platelets is overlaid by a shell of less-activated platelets. Dense
packing in the core acts as a molecular trap, establishing an environment in which diffusion replaces convection.
This structure allows thrombin and other agonists to form overlapping gradients that produce regional differences
in platelet activation and fibrin distribution. Recognizing that transport is regulated by platelet packing density is
a paradigm shift, suggesting that platelet procoagulant activity arises from forming a sheltered environment and
not just from phospholipid exposure. We believe that this concept is key to understanding the impact of
antiplatelet agents and the events of arterial thrombosis. Testing it calls for scaling up to larger injuries in larger
vessels, and for extending our analysis from mice to humans and from hemostasis to thrombosis, all with a
hybrid experimental and computational approach that integrates with and supports the other projects in this PPG.
Aim #1 will examine the spatial and temporal distribution of platelet activation at high resolution, measure
transport in the gaps between platelets, and examine the hemostatic response in large arteries and veins. The
initial results show a more complex architecture with regions of greater and lesser platelet activation and packing
density, and large differences between the luminal and abluminal surfaces. Our subcontract with Brian Storrie at
the University of Arkansas will allow 3-dimensional reconstruction of larger hemostatic thrombi at the sub-micron
level. In collaboration with Project 4 we will examine the impact of sepsis and systemic inflammation on platelet
function in vivo and support studies on the impact of the PF4-directed antibody, KKO. Studies with µ- and m-
calpain deficient mice will support work in Project 2, but also be part of understanding the role of clot retraction
in limiting transport through larger hemostatic structures. Aim #2 will examine the mechanisms that shape the
hemostatic plug, testing the hypothesis that hemostatic structure requires tight regulation of the extent of platelet
activation and the delivery of platelet cargoes deep within the hemostatic mass. Studies on NBEAL2-/- (gray
platelet syndrome) mice and the “empty a-granule” mice developed in Project 1 will allow us to examine the role
of secretion on hemostatic plug architecture. Aim #3 will determine whether the ordered hemostatic structure
that we have observed in mice applies to humans, and how it differs in arterial thrombosis as compared to
hemostasis. The human studies will be performed in vivo with Penn trauma surgeon, Carrie Sims, and ex vivo
using a novel microfluidics device developed with Dan Huh in Penn’s School of Engineering. Studies of human
arterial thrombi will be done in collaboration with Project #2 co-investigator John Weisel.
项目3摘要
血小板活化是止血的关键,也是血栓形成的一个促成因素。尽管最近的研究表明
强调了血小板在不同过程中的作用,大量血小板的快速积累仍然存在
止血和动脉血栓形成的标志,也是这个项目的主要焦点。我们最近在中国的研究
小鼠的微血管系统显示,对轻微损伤的止血反应产生相对简单的
一种结构,在这种结构中,完全激活的血小板的核心被活性较低的血小板的外壳覆盖。稠密
堆芯中的堆积起到了分子陷阱的作用,建立了扩散取代对流的环境。
这种结构允许凝血酶和其他激动剂形成重叠的梯度,从而产生区域差异
在血小板活化和纤维蛋白分布方面。认识到转运是由血小板堆积密度调节的
一种范式的转变,表明血小板促凝血活性来自于形成一个庇护的环境和
不只是因为接触了磷脂。我们认为,这一概念是理解
抗血小板药物与动脉血栓形成事件。测试它需要扩大到更大规模的伤害
血管,并将我们的分析从小鼠扩展到人类,从止血到血栓,所有这些都是通过
混合实验和计算方法,与本PPG中的其他项目集成并提供支持。
目标1将在高分辨率下检查血小板激活的时空分布,测量
在血小板之间的缝隙中运输,并检查大动脉和静脉的止血反应。这个
初步结果显示一个更复杂的结构,有更多和更少的血小板活化和堆积区域
密度,以及管腔表面和管腔表面之间的巨大差异。我们与Brian Storrie的分包合同在
阿肯色大学将允许在亚微米范围内对更大的止血血栓进行三维重建
水平。与项目4合作,我们将研究脓毒症和全身炎症对血小板的影响
体内功能和支持研究PF4导向的抗体KKO的影响。使用µ-和m-的研究
钙蛋白缺乏的小鼠将支持项目2中的工作,但也是理解凝块回缩作用的一部分
限制通过较大止血结构的运输。目标#2将研究塑造
止血塞,测试止血结构需要严格调节血小板范围的假设
血小板的激活和输送深入止血块内部。NBEAL2-/-(灰色)的研究
血小板综合征)小鼠和在项目1中开发的“空a-颗粒”小鼠将允许我们检查其作用
止血塞结构上的分泌物。目标3将确定有序的止血结构
我们在老鼠身上观察到的结果也适用于人类,以及与人类相比,它在动脉血栓形成方面有何不同
止血。人体研究将与宾夕法尼亚大学创伤外科医生凯莉·西姆斯一起在体内进行,并在体外进行
使用一种与宾夕法尼亚大学工程学院的Dan Huh共同开发的新型微流体设备。关于人类的研究
动脉血栓将与项目2的合作研究员John Weisel合作完成。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
LAWRENCE F BRASS其他文献
LAWRENCE F BRASS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('LAWRENCE F BRASS', 18)}}的其他基金
A systems approach to hemostasis and thrombosis
止血和血栓形成的系统方法
- 批准号:
10161823 - 财政年份:2020
- 资助金额:
$ 55.14万 - 项目类别:
Studies of Physiologic and Pathologic Platelet Plug Formation
生理和病理血小板栓子形成的研究
- 批准号:
10161819 - 财政年份:2020
- 资助金额:
$ 55.14万 - 项目类别:
Studies of Physiologic and Pathologic Platelet Plug Formation
生理和病理血小板栓子形成的研究
- 批准号:
10656284 - 财政年份:2020
- 资助金额:
$ 55.14万 - 项目类别:
Studies of Physiologic and Pathologic Platelet Plug Formation
生理和病理血小板栓子形成的研究
- 批准号:
10434806 - 财政年份:2020
- 资助金额:
$ 55.14万 - 项目类别:
A systems approach to hemostasis and thrombosis
止血和血栓形成的系统方法
- 批准号:
10656296 - 财政年份:2020
- 资助金额:
$ 55.14万 - 项目类别:
Regulation of the early events of platelet activation
血小板活化早期事件的调节
- 批准号:
8456213 - 财政年份:2010
- 资助金额:
$ 55.14万 - 项目类别:
Regulation of the early events of platelet activation
血小板活化早期事件的调节
- 批准号:
8242745 - 财政年份:2010
- 资助金额:
$ 55.14万 - 项目类别:
Regulation of the early events of platelet activation
血小板活化早期事件的调节
- 批准号:
8065935 - 财政年份:2010
- 资助金额:
$ 55.14万 - 项目类别:
Regulation of the early events of platelet activation
血小板活化早期事件的调节
- 批准号:
7888575 - 财政年份:2010
- 资助金额:
$ 55.14万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 55.14万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 55.14万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 55.14万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 55.14万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 55.14万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 55.14万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 55.14万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 55.14万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 55.14万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 55.14万 - 项目类别: